Acknowledgements
Presented in part at the 56th Annual Meeting of the American Society of Hematology, December 6–9, 2014, San Francisco, CA.
Potential conflict of interest
Harrys A. Torres is a consultant for Janssen Pharmaceuticals, Gilead Sciences, Merck & Co., Vertex Pharmaceuticals, Novartis, Genentech, Astellas, Pfizer, and Theravance and received research grants from Gilead Sciences, Merck & Co., and Vertex Pharmaceuticals. All other authors had no potential conflicts of interest to disclose. Disclosure forms provided by the authors are available with the full text of this article at http://dx.doi.org/10.3109/10428194.2015.1099649